Regeneron AMD (ONYX)
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as TherapY for Neovascular Age-Related Macular Degeneration: Evaluation of a FiXed Combinatino Intravitreal Injection (ONYX)

A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration

Study Site: We are enrolling patients in this study at the SOUTH location

Inclusion Criteria:
    1. Men or women ≥50 years of age with active subfoveal CNV secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye as assessed by a central reading center
    2. BCVA ETDRS letter score of 73 to 24 (Snellen equivalent of 20/40 to 20/320) in the study eye.
    3. Willing and able to comply with clinic visits and study-related procedures.
    4. Provide signed informed consent
Exclusion Criteria:
    1. Evidence of CNV due to any cause other than AMD in either eye
    2. Prior IVT anti-VEGF in the study eye
    3. Evidence of DME or diabetic retinopathy (defined as more than 1 microaneurysm) in either eye in diabetic patients
    4. Any history of macular hole of stage 2 and above in the study eye
Principal Investigator:

Dr. Kevin J. Blinder

Sub Investigators:

Dr. Gaurav K. Shah
Dr. Bradley T. Smith
Dr. Abdallah Jeroudi
Dr. Yicheng Chen

Website Builder